CPT2
Carnitine O-palmitoyltransferase 2, mitochondrial
Also known as: CPT1, CPT2_HUMAN, CPTASE
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P23786
- Gene
- CPT2
- Ensembl
- ENSG00000157184
- Chromosome
- 1
- Canonical length
- 658 aa
- Protein class
- Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Nucleoli,Mitochondria
OverviewNCBI Gene
The protein encoded by this gene is a nuclear protein which is transported to the mitochondrial inner membrane. Together with carnitine palmitoyltransferase I, the encoded protein oxidizes long-chain fatty acids in the mitochondria. Defects in this gene are associated with mitochondrial long-chain fatty-acid (LCFA) oxidation disorders. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
658 residues, UniProt reviewed canonical sequence.
>P23786|CPT2
1 MVPRLLLRAW PRGPAVGPGA PSRPLSAGSG PGQYLQRSIV PTMHYQDSLP RLPIPKLEDT
61 IRRYLSAQKP LLNDGQFRKT EQFCKSFENG IGKELHEQLV ALDKQNKHTS YISGPWFDMY
121 LSARDSVVLN FNPFMAFNPD PKSEYNDQLT RATNMTVSAI RFLKTLRAGL LEPEVFHLNP
181 AKSDTITFKR LIRFVPSSLS WYGAYLVNAY PLDMSQYFRL FNSTRLPKPS RDELFTDDKA
241 RHLLVLRKGN FYIFDVLDQD GNIVSPSEIQ AHLKYILSDS SPAPEFPLAY LTSENRDIWA
301 ELRQKLMSSG NEESLRKVDS AVFCLCLDDF PIKDLVHLSH NMLHGDGTNR WFDKSFNLII
361 AKDGSTAVHF EHSWGDGVAV LRFFNEVFKD STQTPAVTPQ SQPATTDSTV TVQKLNFELT
421 DALKTGITAA KEKFDATMKT LTIDCVQFQR GGKEFLKKQK LSPDAVAQLA FQMAFLRQYG
481 QTVATYESCS TAAFKHGRTE TIRPASVYTK RCSEAFVREP SRHSAGELQQ MMVECSKYHG
541 QLTKEAAMGQ GFDRHLFALR HLAAAKGIIL PELYLDPAYG QINHNVLSTS TLSSPAVNLG
601 GFAPVVSDGF GVGYAVHDNW IGCNVSSYPG RNAREFLQCV EKALEDMFDA LEGKSIKSLocalizationUniProt · AlphaFold · HPA
Whether an antibody against CPT2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Other membrane
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.23
- Highest tissue expression
- 85 nTPM
Expression across tissuesHPA
Tissue
- liver: 85 nTPM
- colon: 33 nTPM
- kidney: 33 nTPM
- tongue: 31 nTPM
- rectum: 31 nTPM
- duodenum: 31 nTPM
Single-cell type
- cytotrophoblasts: 108 nCPM
- hepatocytes: 102 nCPM
- early primary spermatocytes: 71 nCPM
- syncytiotrophoblasts: 69 nCPM
- retinal pigment epithelial cells: 64 nCPM
- colonocytes: 49 nCPM
Immune cell
- non-classical monocyte: 21 nTPM
- intermediate monocyte: 20 nTPM
- myeloid DC: 18 nTPM
- eosinophil: 15 nTPM
- classical monocyte: 14 nTPM
- naive CD4 T-cell: 11 nTPM
Brain region
- choroid plexus: 33 nTPM
- thalamus: 16 nTPM
- white matter: 16 nTPM
- medulla oblongata: 15 nTPM
- basal ganglia: 14 nTPM
- cerebellum: 14 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about CPT2.
Disease | AllUniProt
Conditions CPT2 is implicated in, by any mechanism.
- Carnitine palmitoyltransferase 2 deficiency, myopathic, stress-induced (CPT2D) MIM:255110
- Carnitine palmitoyltransferase 2 deficiency, infantile (CPT2DI) MIM:600649
- Carnitine palmitoyltransferase 2 deficiency, lethal neonatal (CPT2DLN) MIM:608836
- Encephalopathy, acute, infection-induced, 4 (IIAE4) MIM:614212
Disease | GeneticClinVar
226 pathogenic / likely-pathogenic of 1,151 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Carnitine palmitoyltransferase II deficiency
- Carnitine palmitoyl transferase II deficiency, severe infantile form
- Encephalopathy, acute, infection-induced, susceptibility to, 4
- Carnitine palmitoyl transferase II deficiency, myopathic form
- Carnitine palmitoyl transferase II deficiency, neonatal form
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.17
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.4
- DepMap mean gene effect
- -0.11
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- carnitine metabolic process
- carnitine shuttle
- fatty acid beta-oxidation
- in utero embryonic development
- long-chain fatty acid metabolic process
- positive regulation of cold-induced thermogenesis
Molecular functions
- acyltransferase activity
- carnitine O-octanoyltransferase activity
- carnitine O-palmitoyltransferase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of CPT2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads CPT2 as an antibody target. Whether an autoantibody or antibody against CPT2 could matter depends on whether native CPT2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
CPT2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label CPT2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...